Page 1

teva IR Contacts TEVA REPORTS FIRST QUARTER 2021 FINANCIAL RESULTS • Revenues of $ 4.0 billion • GAAP diluted EPS of $ 0.07 • Non - GAAP diluted EPS of $ 0.63 • Cash flow used in operating activities of $ 405 million • Free cash flow of $ 59 million • Full year 2021 business outlook reaffirmed : O Net revenues of $ 16.4-16.8 billion EBITDA of $ 4.8 - $ 5.1 billion ○ EPS of $ 2.50 - $ 2.70 ○ Free cash flow of $ 2.0 - $ 2.3 billion Tel Aviv , April 28 , 2021 - Teva Pharmaceutical Industries Ltd. ( NYSE and TASE : TEVA ) today reported results for the quarter ended March 31 , 2021 . Mr. Kåre Schultz , Teva's President and CEO , said , " As the COVID - 19 pandemic continues to impact the world and our industry , our employees continue to work together to meet the needs of our customers and patients , all while we remain focused on our long - term goals and laying the foundation for future growth . " We have improved our profitability and reduced our net debt to $ 23.2 billion . We have also seen solid performance from our key growth drivers : the biosimilar TruximaⓇ increased its market share to 26 % , AUSTEDOⓇ continued its year - over - year growth , and AJOVYⓇ solidified its market share in the U.S. and continues to expand in Europe . Based on our results and expectations for the remainder of the year , we are reaffirming our guidance . " First Quarter 2021 Consolidated Results Revenues in the first quarter of 2021 were $ 3,982 million , a decrease of 9 % or 10 % in local currency terms , compared to the first quarter of 2020. This decrease was mainly due to lower revenues from generic , OTC and respiratory products and from COPAXONE in our Europe segment , lower revenues from Anda , COPAXONE and BENDEKA / TREANDA in our North America segment , lower revenues from Japan resulting from the divestment of a majority of the generic and operational assets of our Japanese business venture , as well as regulatory price reductions and generic competition to off - patented products in Japan , partially offset by higher revenues from generic products and AUSTEDO in our North United States Kevin C. Mannix Yael Ashman ( 215 ) 591-8912 972 ( 3 ) 914-8262 PR Contacts United States Israel Kelley Dougherty Yonatan Beker ( 973 ) 832-2810 972 ( 54 ) 888 5898